LNP Delivery Platform

Arbutus’ Lipid Nanoparticle (LNP) technology represents the most widely adopted RNAi delivery technology to date. Administered intravenously, our LNP delivery technology allows RNAi drugs to be encapsulated in tiny particles made of lipids (fats or oils). These tiny particles – LNP – travel through the bloodstream to target tissues.


LNPs are designed to stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. Through a process called endocytosis, cells take up the LNPs which allows them to migrate into the cell. The LNPs then undergo an interaction within the cell and the RNAi trigger molecules are released, mediating RNAi.

The Benefits of LNP Technology

To realize the tremendous therapeutic potential of RNAi-based drugs, effective delivery is critical. Our proprietary delivery technology:

  • Protects the potent trigger in a LNP;
  • Distributes it rapidly and efficiently;
  • Releases it inside the cell; and,
  • Minimizes immunotoxicity and other undesired side effects.


Additionally, multi-dosing with LNP has proven to be well-tolerated with treatments out to one year.

Development of LNP-Based Products

Our manufacturing process is rapid, scalable, and highly reproducible – enabling the commercialization of LNP-based products. In collaboration with the U.S. Department of Defense (DoD) on our TKM-Ebola program, we developed a number of innovations for our LNP delivery technology, such as a “commercial-scale” manufacturing process and ability to lyophilize (freeze-dry) LNP.

Worldwide Leader in the Field of RNAi

We continue to demonstrate leadership in the industry by making innovations to our LNP technology to enable RNAi therapeutics. These innovations include, but are not limited to:

  • Developing groundbreaking LNP potency;
  • Creating lyophilized LNP formulations that maintain the potency of the liquid formulations;
  • Enabling LNP formulations to be administered subcutaneously; and,
  • Custom-designing LNP for respiratory and agricultural applications.


Read more about RNAi Therapeutics in our R&D Portfolio.